Anthocyanins, a sub-class of the flavonoid family of phenolic phytochemicals, may have significant vasoprotective activity (1) , but their low bioavailability suggests bioactivity could be mediated by degradation products or metabolites (2) . The present study aimed to investigate vascular bioactivity of selected anthocyanins and phenolic degradants, and potential synergy between flavonoids and ascorbic acid. Bioactivity was assessed by human umbilical vein endothelial cell (HUVEC) superoxide production and expression of NAD(P)H oxidase (NOX), and production of nitric oxide (NO) and expression of endothelial NO synthase (eNOS).
NOX expression was not significantly altered by anthocyanin degradants (data not shown). No significant modulation of NO decomposition products was observed, however cyanidin-, peonidin-and petunidin-glucosides significantly (P < 0.05) upregulated eNOS (data not shown). In conclusion, anthocyanins and their phenolic degradants decreased superoxide production, whilst only anthocyanins upregulated eNOS, suggesting differential bioactivity of anthocyanins and degradants. Given the low bioavailability of anthocyanins in vivo, their phenolic degradants may enhance vascular function by decreasing superoxide production and thus NO scavenging, as opposed to direct stimulation of NO production. This work was supported by a BBSRC-CASE studentship (M. Edwards) in partnership with GlaxoSmithKline plc. (United Kingdom).
